Lumos Diagnostics Holdings Limited (ASX:LDX)

95.0¢

right-arrow Created with Sketch. -0.02 (-2.06%)
MCAP $146.0M
Last trade 15.59pm 25/01/2022 20mins delayed

Latest Announcements

12/01/2022LDXLumos Diagnostics Holdings Limited
12/01/2022 Price SensitivePSLDXLumos Diagnostics Holdings Limited
24/12/2021LDXLumos Diagnostics Holdings Limited
24/12/2021LDXLumos Diagnostics Holdings Limited
24/12/2021LDXLumos Diagnostics Holdings Limited
24/12/2021LDXLumos Diagnostics Holdings Limited
24/12/2021LDXLumos Diagnostics Holdings Limited
22/12/2021 Price SensitivePSLDXLumos Diagnostics Holdings Limited

Company Overview

Lumos Diagnostics Holdings Limited (Lumos) is an Australia-based company that develops, manufactures and commercializes point-on-care (POC) diagnostic test solutions. The Company's solutions help healthcare professionals to accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and digital reader platforms. The Company's portfolio of product, technology and service offerings include Point-of-care diagnostic products, Point-of-care readers, Commercial services and Manufacturing services. The Company's products include FebriDx and CoviDx. FebriDx is an all-in-one point-of-care test device that can differentiate a viral from bacterial acute respiratory infection. CoviDx is a rapid immunoassay for the detection of the nucleocapsid protein in nasal swabs (NS), oropharyngeal swabs (OP), and nasopharyngeal swabs (NP) from patients suspected of a Coronavirus-19 (COVID-19) infection.

LDX in the news

A new clinical service has been launched at more than 100 pharmacies…
Lumos Diagnostics (LDX) has completed all activities to gain regulatory approval in…
Lumos Diagnostics (LDX) receives US$250,000 (A$352,600) in initial orders for its rapid…
Lumos Diagnostics (LDX) receives authorisation to sell its COVID-19 rapid diagnostic test…

Search Previous Announcements